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Molecular Characterization of the Ro/SS-A
Autoantigens
Daniel P. McCauliffe and Richard D. Sontheimer
Molecular techniques have recently revealed that there are several immunologically distinct Ro/SS-A antigens. Three genes
encoding putative Ro/SS-A protein antigens with calculated masses of 46, 52, and 60 kD have been isolated. The encoded
amino acid sequence of each is quite dissimilar. The 46-kD antigen is calreticulin (CR), a highly conserved calcium-binding
protein that resides predominately in the endoplasmic reticulum where it may be involved in protein assembly. Although
CR has recently been confirmed to be a new human rheumatic disease-associated autoantigen, its relationship to the
other components of the Ro/SS-A ribonucleoprotein has become somewhat controversial owing predominately to the fact
that recombinant forms of calreticulin have not displayed the same pattern of autoantibody reactivity possessed by the
native form of this protein. The 52-kD antigen most likely resides in the nucleus and may be involved in the regulation of
gene expression. The cellular location and function of the 60-kD antigen is uncertain but studies indicate that it is a RNA-
binding protein. The 46- and 60-kD antigens share homology with foreign polypeptides, suggesting that an immune
response initially directed against a foreign protein may give rise to the autoimmune response directed at cross-reacting self
proteins. J Invest Dermatol 100:73S–79S, 1993
In 1969 Clark et al first demonstrated a novel antigen in human tissue
extracts that by immunodiffusion analysis reacted with sera from patients
with systemic lupus erythematosus and Sjo¨gren’s syndrome [1]. This
antigen and its reactive autoantibodies were called Ro (auto)antigen and
Ro (auto)antibodies, respectively. In 1975 Alspaugh and Tan similarly
demonstrated the presence of three different autoantibodies in sera from
patients with Sjo¨gren’s syndrome that they designated SS-A, SS-B, and
SS-C [2]. Later it was demonstrated that SS-A autoantibodies were
immunologically equivalent to the Ro autoantibodies [3], and thus we
now commonly preface these autoantibodies and their respective
antigens with the term Ro/SS-A. SS-B autoantibodies were also shown
to be identical to La autoantibodies, a specificity that frequently
accompanies Ro/SS-A autoantibodies [3].
CLINICAL SIGNIFICANCE OF THE Ro/SS-A ANTIGENS
AND ANTIBODIES
The Ro/SS-A antigens are of clinical interest in that antibodies directed
against them are found in the majority of patients with primary Sjo¨gren’s
syndrome, subacute cutaneous lupus erythematosus (SCLE), neonatal
lupus erythematosus (NLE), anti-nuclear antibody (ANA) negative lupus
erythematosus (LE), and systemic LE-like disease secondary to homo-
zygous C2 or C4 complement deficiency [4–9]. Substantial evidence
indicates that they play a major role in the pathogenesis of disease
[10,11]. The strongest evidence comes from observations in patients with
NLE. Pregnant mothers with circulating Ro/SS-A autoantibodies can pass
them across the placenta to their fetus. The fetus can develop congenital
heart block, hepatic inflammation, and thrombocytopenia from tissue
injury presumably caused by these antibodies [12,13]. Additionally,
shortly after birth and perhaps triggered by ultraviolet (UV) light
exposure, these infants can develop skin lesions clinically and
histopathologically similar to those of SCLE [12]. In several months, as
the maternally acquired antibodies are cleared from the infant’s
circulation, the skin lesions resolve [12].
Investigative work has provided additional evidence that Ro/SS-A
antibodies may be pathogenic. Ro/SS-A antibodies administered intrave-
nously to immunodeficient mice engrafted with human skin bind
preferentially in and about the human basal keratinocytes [14]. This
binding is augmented by UV light exposure. This pattern of immunoglo-
bulin deposition is identical to that found in biopsies from NLE and SCLE
skin lesions.
CHARACTERIZATION OF THE Ro/SS-A ANTIGENS
Since Clark et al first demonstrated the presence of Ro/SS-A auto-
antibodies by immunodiffusion studies in 1969[1], we have learned a
great deal more about their target antigens.
In 1981 Lerner et al demonstrated that human Ro/SS-A autoimmune
sera immunoprecipitated a novel class of small RNAs that they
designated the human (h) cYtoplasmic (Y) RNAs or hY RNA [15]. In
1984 Wolin and Steitz showed that this hY RNA immuno-precipitation
resulted from the binding of Ro/SS-A autoantibodies to a 60-kD protein
to which the hY RNAs were apparently linked [16]. From 1984 until
1988 it was generally thought that Ro/SS-A autoantibodies were directed
at a single 60-kD protein. However, in 1988 Ben-Chetrit et al
demonstrated a novel 52-kD Ro/SS-A antigen by immunoblot analysis
that was immunologically distinct from the 60-kD antigen [17]. In 1989
Rader et al demonstrated four immunologically distinct antigens that
react with monospecific Ro/SS-A autoimmune sera [18]. Over the past
four years genes encoding 60-, 46-, and 52-kD autoantigens have been
isolated.
60-kD Ro/SS-A In 1988 Deutscher et al reported the cloning of a 60-kD
Ro/SS-A antigen from a human placental complementary (cDNA) library
[19]. In 1989 Ben-Chetrit et al [20] reported the cDNA sequence cloned
from a human T-cell leukemia cDNA library that appeared to be a
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homologous gene or a differentially spliced version of the gene
characterized by Deutscher et al. Deutscher’s and Ben-Chetrit’s
sequences both encoded a 60-kD protein that was identical except for
several amino acids at the carboxy-terminus. Both amino acid sequences
contain a zinc finger motif and a sequence motif common to RNA
binding proteins [19,20]. Zinc fingers are thought to serve as a site of
nucleic acid binding or protein binding [21].
There is no extensive sequence homology between the 60-kD protein
and other published protein sequences; however, six segments of this
protein have limited homology to different portions of a vesicular
stomatitis virus (VSV) nucleocapsid protein [22]. Five of these homo-
logous regions have significant reactivity to human Ro/SS-A autoimmune
sera by enzyme-linked immunosorbent assay (ELISA), which suggests that
an immune response initially directed at the VSV protein or a similar viral
protein might cross-react with the 60-kD Ro/SS-A protein by way of its
cross-reacting epitopes. VSV is not known to be particularly pathogenic
in humans, but the data suggest that this VSV protein or a similar viral
protein might elicit the Ro/SS-A autoimmune response. This is an
example of ‘‘molecular mimicry’’ where a microbial protein is thought to
trigger an immune response that cross-reacts with a self-antigen [23].
46-kD Ro/SS-A Our group isolated a cDNA from an Epstein-Barr virus
transformed human B-cell line that encodes a protein reactive with human
Ro/SS-A autoimmune sera [24]. The encoded 46-kD protein migrates
aberrantly at 60kD by sodium dodecylsulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE). The amino acid sequence of this 46-kD molecule
reveals a hydrophobic leader sequence at its amino terminal typical of
molecules transported into the endoplasmic reticulum (ER), and a KDEL
carboxy terminal sequence that is classic for proteins that are retained in the
ER [24,27]. This sequence is extremely homologous to murine and rabbit CR
(94% and 92%, respectively) [28]. CR is a calcium-binding protein that
resides in the endoplasmic and sarcoplasmic reticulum [29]. From this high
degree of sequence homology and other data it has been concluded that the
46-kD molecule is human CR [28,30].
Recent evidence indicates that CR may be coordinately expressed
with the glucose-regulated protein (GRP)78, GRP94, and protein
disulfide isomerase (PDI) genes [31]. The protein products of all four of
these genes are highly acidic, localize to the ER, and bind calcium [32].
GRP78 and GRP94 are highly homologous to heat-shock proteins
[33,34]. Both of these proteins and PDI are thought to play a major role in
protein assembly within the ER [33–35]. Thus, by implication, CR may
also play a role in protein assembly.
It is also interesting to note that patients infected with Onchocerca
volvulus, a filarial nematode that causes river blindness, sclerosing
lymphadenitis, and dermatologic disease in humans residing in parts of
Africa and Central America, have antibodies directed against the Ral-1
antigen, which is highly homologous to CR [28,36]. Although patients
with this nematode are not at increased risk for developing Sjo¨gren’s
syndrome or LE, this homology between CR and a filarial protein raises
the possibility that a foreign Ro/SS-A protein equivalent might trigger the
autoimmune Ro/SS-A antibody response seen in some patients with
Sjo¨gren’s syndrome and several LE-related disorders. Drosophila
melanogaster and the marine snail Aplysia californka have molecules
similar to CR [28].
Work recently presented by other laboratories has now confirmed our
initial suggestion that calreticulin is a rheumatic disease-associated
autoantigen [37,38]. One group has found that an Escherichia coli
recombinant form of human calreticulin reacted by ELISA with 40% of
the serum samples from unselected SLE patients [37], whereas another
group found 33% of their SLE sera to react with the same form of
recombinant CR by Western blot [38]. Curiously, neither group found a
significant correlation between anti-CR and anti-Ro/SS-A autoantibody
levels in their SLE patient sera.
We have reason to believe that post-translational modification such
as phosphorylation, perhaps through the augmentation of hY RNA
binding, could also be relevant to the configuration of CR that is recognized
by Ro/SS-A autoantibodies. Non-mammalian forms of recombinant CR are
unlikely to possess the same pattern of RNA binding or phosphorylation that
is displayed by the native configuration of CR present in mammalian cells.
The concern that CR may not be a component of the Ro/SS-A RNP complex
stems from the fact that recombinant forms of CR both in our laboratory
(personal unpublished observation) and in others [37,38] do not display the
same degree of reactivity with Ro/SS-A autoantibodies that has previously
been demonstrated with native human CR purified from human Wil-2 cells.
We now have evidence that the protein-RNA binding site present on a
subpopulation of CR molecules that bind hY RNA contributes to the structure
that is being recognized by human anti-Ro/SS-A autoantibodies [39].
52-kD Ro/SS-A Chan et al and Itoh et al independently isolated the same
cDNA sequence from two different human T-cell cDNA libraries that
encodes a 52-kD protein reactive with human Ro/SS-A autoimmune sera
[40,41]. The amino acid sequence predicted by this cDNA contained
leucine zipper and zinc finger binding motifs and also had significant
homology with the human ret transforming protein and the murine T-cell
regulatory protein rpt-1, which are thought to play a role in gene
regulation [40,41]. These sequence motifs and homologies suggest that
the 52-kD Ro/SS-A molecule may be involved in gene regulation and
thus probably resides in the nucleus.
There are no significant sequence homologies between the 60-, 46-,
or 52-kD antigens (Table I). Despite the knowledge gained from
analyzing the encoded amino acid sequences of each Ro/SS-A cDNA,
there still remain a number of unanswered questions that several
investigators have started to address.
Are These Antigens Structurally Associated and What Are Their
Relationships to the hY RNAs? Ro/SS-A autoimmune sera from patients
with LE and Sjo¨gren’s syndrome immunoprecipitate four hY RNAs (hYl,
3, 4, and 5) from human cell extracts [15] (see Fig 1). Antisera specific for
either a 52-kD or a 60-kD protein have been shown to immunopreci-
pitate the hY RNAs from cellular extracts. However, in one study
whenever 52-kD specific antibodies (not reactive to the 60-kD antigen by
immunoblot analysis) were used, the hY RNAs and 52-kD protein were
precipitated along with a small amount of 60-kD protein [17]. Thus it is
not certain whether 1) the 52-kD species binds the hY RNAs directly; 2)
the 52-kD protein is indirectly associated with the hY RNA through a
direct association with a 60-kD hY RNA binding protein; or 3) the
antibodies that appeared specific for the 52-kD antigen by immunoblot
may recognize a cross-reactive epitope on the native Ro/SS-A ribonu-
cleoprotein (RNP) particle.
Deutscher et al have demonstrated that the 60-kD Ro/SS-A protein
directly associates with hY RNAs in reconstitution studies [19]. There is
some evidence that CR associates with the hY RNA as suggested by UV
cross-linking studies [24], immunoprecipitation of hY RNA by affinity-
purified CR antisera [24], and the fact that onchocerciasis patient sera
with CR reactive antibodies can immunoprecipitate hY RNA [42].
Additionally, preliminary data indicate that rabbit antisera raised against
two synthetic peptides corresponding to different portions of the CR
Table I. Characteristics of Three Ro/SS-A cDNA-
Encoded Products
Protein Location Function Homology
Pathogenic
Role
60 kD Nuclear?
Cytoplasmic?
RNA binding VSV
nucleocapsid
protein
Molecular
mimicry?
46 kD Predominantly
cytoplasmic±
nuclear
Ca++ binding
Protein folding?
Calreticulin
Ral-1
Translocation
Parasite
homology?
52 kD Predominantly
nuclear±
cytoplasmic
Gene
regulation?
rfp, rpt-1
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amino acid sequence can precipitate hYRNA [39]. However, the
relationships that exist between CR and the other molecular constituents
of the Ro/SS-A RNP particle continue to be debated [38,43,44].
Earlier data suggested that Ro/SS-A autoimmune sera precipitated a
60-kD protein along with the hY RNA and this immunopre-cipitation was
dependent on the presence of protein [15]. More recently Boire and Craft
have identified Ro/SS-A antibodies that specifically immunoprecipitate
hY5 RNA and a 60-kD protein, but not the other types of hY RNA [45].
They concluded that some Ro/SS-A autoimmune sera contain auto-
antibodies directed at a con-formational epitope that is expressed only
on Ro/SS-A-hY5 RNA particles but absent on hY1, 2, 3, and 4 containing
particles.
The 60-kD protein immunoprecipitated in the above studies most
probably represents the authentic 60-kD protein as its amino acid
sequence contains a sequence motif typically found in RNA-binding
proteins, although it is clear that proteins without the classic RNA-
binding consensus sequence can also bind RNA molecules [46,47]. The
hY RNAs and Ro/SS-A proteins might exist in a RNP multimeric complex
similar to the Ul RNPs. One could hypothesize that the zinc finger motif
in the 60-kD Ro/SS-A molecule might serve as a site for this protein to
bind one or more of the other Ro/SS-A molecules, whereas the RNA
binding motif would serve as a site of hY RNA binding.
Several different investigators have reported different masses for the
Ro/SS-A RNP particle. Three groups have reported a mass of approxi-
mately 100–150 kD for the Ro/SS-A particle as determined by gel
filtration [1,48,49]. Wolin and Steitz determined that the particle
sediments in sucrose at approximately 7S [16]. This is equivalent to
B93 kD, which could be accounted for by the mass of one 60-kD protein
and the average mass of one hY RNA molecule. Boire and Craft
biochemically purified Ro/SS-A particles and found them to partition into
three different groups by sucrose sedimentation gradients [50]. The
particles in two of these groups have a mass of approximately
300–350 kD by gel filtration and the other has a mass of approximately
230 kD. These investigators concluded that Ro/SS-A RNP particles are
heterogeneous and may exist as multimeric units consisting of hY RNA, a
60-kD protein, and perhaps other polypeptides including the La/SS-B
protein [50] (see Fig 2).
Some investigators argue that if a particular protein reactive with Ro/
SS-A autoantibodies is not part of the hY RNA-bearing RNP complex,
then perhaps it should not be called a Ro/SS-A antigen. Although this is a
matter of semantics, there is a clear need to develop a more precise
designation for each of these antigens. However, it should be
remembered that Ro/SS-A antigens were initially defined by immuno-
diffusion assays, not by hY RNA association. It has not yet been
determined which of the molecules reactive with Ro/SS-A autoimmune
sera are responsible for the immunoprecipitate seen in immunodiffusion
assays. Rader et al, however, observed that non-reducing SDS-PAGE of
eluted precipitins from counter-immunoelectrophoresis showed the
precipitins to be composed of a 60-kD protein [18].
What Is the Cellular Distribution of Each Ro/SS-A Molecule? Some
investigators have reported predominantly intranuclear localization of
the Ro/SS-A antigens by indirect immunofluorescence [51–54] whereas
others have reported cytoplasmic [55–57] or both cyto-plasmic and
nuclear localization [58,59]. Whether this discrepancy in subcellular
localization is related to the method of cell fixation, cell substrate, or the
specificity of the Ro/SS-A autoimmune sera used has not been fully
investigated.
Koch et al have demonstrated that conventional cell fixation for ANA
testing does not allow full visualization of proteins, such as CR, that
reside in the ER [60]. They demonstrated that ER proteins can be better
visualized by immunofluorescence techniques with detergent permeabi-
lization of fixed cells or of unfixed cells that have been equilibrated in
9% sucrose [60].
Figure 1. hY RNA immunoprecipitation. Wil-2 cells, an EBV transformed
B-cell line, were radiolabeled with 32P-orthophosphoric acid and sonicated.
The resulting cell extract was incubated with sera and the immunoprecipitated
material was harvested and subjected to gel electrophoresis according to
previously established protocols [15]. Lane 1 contains total radiolabeled RNA
from the extract and serves to provide molecular weight standards as indicated to
the left of this lane. Lane 2 demonstrates that no RNA was immunoprecipitated
with normal human serum. Lane 3 is RNA immunoprecipitated with human
autoimmune sera containing both Ro/SS-A and La/SS-B autoantibodies. Lanes 4
and 5 are sera from two different patients with Ro/SS-A autoantibodies as denned
by double immunodiffusion. All three sera with Ro/SS-A autoantibodies
immunoprecipitated the four major types of hY RNA. The very faint unlabeled
band in lane 3 between hYl and hY3 is hY2, a breakdown product of hYl. The
Epstein-Barr virus encoded EBER 1 and 2 immunoprecipitate with La/SS-B
antibodies as previously described [56].
Figure 2. One model of the Ro/SS-A RNP particle. The proposed relationship
between hY RNA and the Ro/SS-A and La/SS-B proteins is indicated. The hY
RNA are RNA polymerase III transcripts and are thought to be at least
transiently associated with the La/SS-B protein through binding of its uridine
rich 30 end. The 60-kD Ro/SS-A protein contains an RNA binding motif
believed to be the site of hY RNA binding. It is uncertain if the 46- and/or 52-
kD proteins reactive with Ro/SS-A autoimmune sera or other polypeptides are
a part of this particle, although there is some evidence that the 46-kD protein
is associated with hY RNA.
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Isolation of antibodies specific for each Ro/SS-A antigenic polypep-
tide has allowed more precise cellular localization of the Ro/SS-A
polypeptides and these results have helped explain the discrepancies
encountered previously with immunofluorescence staining using whole
Ro/SS-A patient sera.
Ben-Chetrit et al demonstrated strong punctate nuclear and slight
cytoplasmic staining of cells with Ro/SS-A autoimmune serum immuno-
affinity purified from a 52-kD protein and also with monospecific
anti- 52-kD serum (as determined by immunoblot analysis) [17]. They
reported an indistinguishable pattern with Ro/SS-A autoimmune serum
immunoaffinity purified from a 60-kD protein [17]. There is some
evidence that there may be Ro/SS-A antibodies that react with an epitope
on the native 60-kD RNP antigen that cross-react with an epitope on the
52-kD protein [61]. Thus one might speculate that the 60-kD protein
resides primarily in the cytoplasm and that nuclear staining results from
antibodies that recognize a cross-reactive epitope on the 52-kD protein.
Preliminary ELISA data have revealed that all Ro/SS-A autoimmune sera
with high-titer antibodies directed against a recombinant 52-kD Ro/SS-A
protein have given a speckled nuclear ANA pattern of fluorescence
(personal unpublished observation). The 52-kD Ro/SS-A amino acid
sequence reveals motifs and homologies that indicate that it may be
involved in gene regulation and thus would likely reside in the nucleus
[40,41]. Antiserum specific for CR has revealed predominantly peri-
nuclear cytoplasmic staining with lesser amounts of nuclear staining
[62,63].
Kato et al have reported that the majority of the hY5 RNA is found in
the cytoplasmic fraction of HeLa cells [64]. More recently Boire and Craft
have demonstrated that more than 90% of the Ro/SS-A particles were
recovered from the cytoplasmic fraction of HeLa cells [50]. One should
recall that Ro/SS-A antigen was originally described as a saline-soluble,
‘‘cytoplasmic’’ autoantigen [1].
Is There Any Correlation Between the Type of Ro/SS-A Autoantibodies
Patients Produce and Their Diagnosis, Disease Course, and/or Response
to Therapy? Preliminary data suggest that patients with Ro/SS-A
autoantibodies might be clinically categorized according to the Ro/
SS-A proteins or epitopes their sera recognize. The specificity of the
maternally acquired Ro/SS-A autoantibodies may determine which
infants develop NLE. Buyon et al have shown that the predominant
antibody response in the NLE patient group with acquired heart block
was directed against the 52-kD Ro/SS-A protein, although some patients
also had antibodies directed against a 60-kD protein [65]. Ben-Chetrit
et al have demonstrated that of 51 SLE patients who were Ro/SS-A
positive by immunodiffusion, 47% had antibodies that recognized both a
60-kD and a 52-kD protein, 18% had antibodies that recognized a 60-kD
protein only, and 35% were nonreactive to both [66]. Similarly, they
demonstrated that of 47 Ro/SS-A -positive Sjo¨gren’s syndrome patients,
47% had antibodies reactive to both a 60-kD and a 52-kD protein, 40%
reacted only with a 52-kD protein only, and 13% were non-reactive.
Unfortunately the results obtained by both Buyon et al and Ben-Chetrit
et al were obtained by immunoblot analysis and might not detect
conformational epitopes, including epitopes that might be present on a
multimeric complex.
Work is currently in progress in several laboratories, including our
own, to determine those portions of each Ro/SS-A molecule to which Ro/
SS-A autoantibodies bind and to define further the nature of conforma-
tional epitopes that may exist on an individual Ro/SS-A protein or as part
of a multimeric structure. Epitope mapping should determine if subsets of
Ro/SS-A autoantibody-associated disease can be based on antigenic site-
recognition patterns. Such subclassification may have clinical use
regarding the pathogenesis, diagnosis, and treatment of the Ro/SS-A
autoantibody-associated diseases.
What Role Do the Ro/SS-A Autoantigens Play in the Pathogenesis of
SCLE and NLE Skin Disease and How Might Their Cellular Expression Be
Affected by Factors that May Influence These Two Skin Diseases?
A number of agents have been shown to influence SCLE and NLE disease
expression. Some of these agents have been shown to displace Ro/SS-A
antigens to the surface of cells (Fig 3).
UV light SCLE and NLE skin diseases are frequently exacerbated by
UV light exposure, primarily of the UVB type (290–320nM) [67,68].
Investigators have demonstrated that UVB light can displace Ro/SS-A
antigen from within keratinocytes to the cell surface [69,70]. Similar
results have recently been reported for the La/SS-B antigen [71]. Such
displacement would allow the autoantigen to have access to the Ro/SS-A
autoantibody binding that could result in tissue injury through comple-
ment-mediated lysis or antibody-dependent cell-mediated cytotoxicity.
At this time it is uncertain which of the various molecular components of
the Ro/SS-A autoantigen complex are affected by UV light exposure.
Recent preliminary studies have indicated that physiologically relevant
doses of UVB induce both CR gene transcription [72] (personal
observation) and translation [73]. However, similar doses of UVB did
not increase cellular levels of the 60-kD Ro/SS-A protein [73]. No
evidence has yet been presented regarding the displacement of the
various Ro/SS-A proteins to the cell surface by UV light.
Estrogens The hormonal milieu may also play an important role in Ro/
SS-A-associated disease, as approximately 75% of SCLE patients and
infants with NLE skin disease are female. Estrogen treatment of cultured
keratinocytes results in increased expression of Ro/SS-A antigens on the
cell surface, but it is uncertain which of the Ro/SS-A molecules are so
displaced [74].
Heat Some SCLE patients have noted that heat can exacerbate their
skin disease [67]. The similarities that CR shares with the heat shock-like
proteins GRP78 and GRP94 is of interest in this regard. There is recent
evidence that heat shock – like proteins can be translocated to the cell
surface, where they may participate in antigen presentation or may be a
target for gamma/delta T-cell-directed cytotoxicity [75,76].
State of keratinocyte differentiation and proliferation Studies have
shown that human keratinocytes grown in low-calcium-containing
culture media have greater amounts of cytoplasmic Ro/SS-A antigen as
detected by immunofluorescence staining with Ro/SS-A autoimmune
sera [59]. It is uncertain which of the Ro/SS-A antigens are expressed in
greater amounts, however. At lower calcium concentrations, cultured
keratinocytes are in a less-differentiated, more rapidly proliferating state,
more like the basal layer keratinocytes [77]. This might explain why the
more rapidly proliferating basal keratinocytes appear to be preferentially
targeted in SCLE and NLE [11,78]. Preliminary evidence indicates that CR
Figure 3. Ro/SS-A translocation. Agents that may translocate Ro/SS-A
antigens to the cell surface where they are available to bind circulating Ro/SS-
A autoantibodies are listed. The likely predominant location of the 46- and
52-kD antigens are indicated. The location of the 60-kD antigen is more
uncertain.
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is expressed at higher levels in rapidly proliferating cells (personal
unpublished observation).
There is some evidence that CR can be transiently secreted from cells
after treatment with calcium ionophores [79], although this has not been
fully substantiated by others [80]. Recent studies in our laboratory
employing calreticulin reporter gene constructs have indicated that
calreticulin transcription is markedly augmented in A431 cells following
treatment with the calcium ionophore ionomycin [72] (personal
unpublished observation). Additionally, it has been suggested that
calcium ionophore treatment of cultured human keratinocytes displaces
Ro/SS-A antigen to the cell membrane, although it is uncertain which of
the Ro/SS-A antigens is (are) so displaced [81].
Infection There is considerable evidence that viral infections can
precipitate or exacerbate autoimmune disease [82]. Some work has
suggested that virally infected cells in culture displace Ro/SS-A antigens
to the cell surface, similar to the effects caused by UV light [83]. Jianhui
and Newkirk have recently presented evidence that suggests that human
cytomegalovirus (CMV) infection increases the expression of CR in MRC-
5, a human embryonic lung fibro-blast line [84]. These studies found that
total cellular CR levels increased following CMV infection, but the
greatest increase in CR antigenicity was associated with the plasma
membrane. CMV infection also resulted in increased intracellular levels
of the 60-kD Ro/SS-A antigen, but similar increases were not observed in
the plasma membrane. Viral infection has also been shown to displace
the La/SS-B antigen from the nucleus [85].
Polymorphism It is not known whether Ro/SS-A proteins are
polymorphic. Preliminary studies have indicated, however, that the CR
encoding gene is not highly polymorphic in normal individuals by
restriction fragment length polymorphism analysis [24]. There is
evidence of at least two forms of the 60-kD Ro/SS-A encoding gene
[18–20]. Kutsch et al have recently reported variability in Ro/SS-A
displacement to keratinocyte membranes after treatment with calcium
ionophore or tumor necrosis factor alpha, which they suggest might arise
from genetic differences in the keratinocyte donors [81]. It is possible that
certain forms of a Ro/SS-A molecule may be more immunogenic,
expressed at higher levels, or more easily displaced to the cell surface
where it could participate in immune-mediated injury.
SUMMARY
With molecular techniques, we have recently learned that there are
several immunologically distinct Ro/SS-A antigens. Three putative Ro/SS-
A genes have been isolated and the encoded proteins from these three
genes have been found to be quite dissimilar. CR, the 46-kD protein,
appears to reside predominately in the endoplasmic reticulum/cyto-
plasm, whereas the 52-kD protein most likely resides in the nucleus. The
structure of the 60-kD protein and at least one immunofluorescence
study suggest that it may also reside predominantly in the nucleus,
although if it is the authentic hY RNA binding protein, it should also
reside in the cytoplasm. The Ro/SS-A RNP particles are heterogeneous
multimeric complexes that may include more than one Ro/SS-A
molecule, hY RNA, La/SS-B, and perhaps other currently undefined
molecules.
Two of the putative Ro/SS-A proteins share significant homology with
foreign proteins, suggesting that an immune response initially directed
against a foreign protein, such as a viral protein, may give rise to the
autoimmune response directed at cross-reacting self Ro/SS-A protein.
This, plus the possibility that viral infection can alter the normal cellular
distribution of Ro/SS-A antigens, presents the intriguing paradigm
illustrated in Fig 4 where virus infection might have a dual impact on
the Ro/SS-A autoimmune response.
Work is in progress to determine if there is an association between
which Ro/SS-A molecules and/or epitopes are targeted by patient
autoimmune sera and patient diagnosis, clinical course, and/ or response
to therapy. We are hopeful that efforts to characterize the structures and
functions of the Ro/SS-A antigens will further elucidate the pathogenesis
of the Ro/SS-A autoantibody-associated diseases and aid in the
development of better diagnostic and therapeutic modalities for those
afflicted.
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